Lilly To Head To FDA After Demonstrating Foundayo’s Cardiovascular, Liver Safety

 
• By Alaric DeArment
  
GLP-1 text written and circled red pencil marker
Lilly announced results from the ACHIEVE-4 trial of Foundayo in type 2 diabetes among overweight and obese adults at risk of a cardiovascular event. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Trial Results

More from R&D